Chemotherapy for gastric cancer patients - Time for personalization in medicine?

Wspolczesna Onkologia

Volumn 16, Issue 1, 2012, Pages 86-89

  Nowara, Elzbieta ^a   Boratyn Nowicka, Agnieszka ^a   Polakiewicz Gilowska, Anna ^a   Drosik, Anna ^a   Kustra, Magdalena ^a   Huszno, Joanna ^a  

^a Institute of Oncology   (Poland)

Author keywords

Chemotherapy; Gastric cancer; Personalization in medicine; Targeted therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; TAXANE DERIVATIVE; TRASTUZUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG APPROVAL; DRUG EFFICACY; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; STOMACH CANCER; TREATMENT RESPONSE;

EID: 84857954988     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.27342     Document Type: Review

References (28)

1. http://epid.coi.waw.pl/krn/
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-9. (Pubitemid 46630593)
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41. (Pubitemid 23182046)
4. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995; 7: 587-91.
5. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-8. (Pubitemid 27112884)
6. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994; 12: 412-6. (Pubitemid 24056417)
7. De Lisi V, Cocconi G, Angelini F, et al. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. Cancer 1996; 77: 245-50.
8. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-8.
9. Roth A, Kolaric K, Zupanc D, Oresic V, Roth A, Ebling Z. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori 1999; 85: 234-8. (Pubitemid 29482207)
10. Cocconi G, Carlini P, Gamboni A, et al. talian Oncology Group for Clinical Research. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003; 14: 1258-63. (Pubitemid 37045322)
11. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7. (Pubitemid 27020582)
12. Vanhoefer U, Rougier P, Wilke H. et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-57. (Pubitemid 30465650)
13. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
14. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-7. (Pubitemid 46631401)
15. Boku N, Yamamoto S, Fukuda H, et al. Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-9.
16. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-7.
17. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, KitajimaM. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996; 2: 909-14. (Pubitemid 26168944)
18. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-9. (Pubitemid 44315804)
19. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-97.
20. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II Study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011; 29: 868-74.
21. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-6. (Pubitemid 46631363)
22. JhawerM. Phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma (abstract #10). American Society of Clinical Oncology GI Cancer Symposium. 2009.
23. Narahara H, Iishi H, Imamura H, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). Gastric Cancer 2011; 14: 72-80.
24. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A; ESMO Guidelines Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v50-4.
25. Boku N. Perspectives for personalization in chemotherapy of advanced gastric cancer. Discov Med 2010; 9: 84-9.
26. Javle M, Hsueh CT. Recent advances in gastrointestinal oncology -updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010, 3: 11.
27. Sun Q, Hang M, Xu W, Mao W, Hang X, Li M, Zhang J. Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer. Jpn J Clin Oncol 2009; 39: 791-6.
28. Asakura H, Hashimoto T, Harada H, et al. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol 2011; 137: 125-30.